The Company intends to use the net proceeds of this offering after payment of the expenses of the offering for the funding of its AG013 clinical trial and lantibiotics programs and for general corporate purposes, including working capital and shall not use such proceeds for the satisfaction of any portion of the Company’s debt (other than trade payables in the ordinary course of the Company’s business and prior practices), or to redeem any Common Stock or Common Stock Equivalents.